Vancouver, British Columbia, May 31, 2024 /PRNewswire/ – Numinus Wellness Inc. (hereinafter “Numinus” or “we”) (TSX:NUMI) (OTCQX:NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announced at its Annual General Meeting of Shareholders (the “meetingAt the Shareholders’ Meeting held today, a total of 50,266,506 common shares were issued, representing 15.68% of the Company’s issued and outstanding common shares of 320,551,600 as of November 31, 2018. April 2, 2024attended the meeting in person or by proxy.
The following six nominees proposed by Numinus have been elected to serve as Numinus’ directors until Numinus’ next annual meeting of stockholders or until their successors are elected or appointed. A summary of the voting results for the elected directors is as follows:
|
director |
Votes |
% vote |
Withhold vote |
Vote Withholding Rate |
|
Payton Nikvest |
24,280,301 |
86.16% |
3,901,707 |
13.84% |
|
Allen Morishita |
21,544,890 |
76.45% |
6,637,118 |
23.55% |
|
Larry Timrick |
26,611,791 |
94.43% |
1,570,217 |
5.57% |
|
Michael Tan |
23,971,074 |
85.06% |
4,210,934 |
14.94% |
|
Donna Wong |
27,017,742 |
95.87% |
1,164,266 |
4.13% |
|
Donna Wilson |
27,018,311 |
95.87% |
1,163,697 |
4.13% |
In addition to the election of all the nominees mentioned as Directors in the Management Information Circular dated April 10, 2024 (“RoundIn the , Numinus shareholders approved all other resolutions submitted to the meeting, including setting the number of Numinus’ directors at six and appointing Davidson & Company LLP as Numinus’ auditors for the coming year.
Further details regarding the resolutions voted on at today’s meeting are set out in the circular documents available for viewing on SEDAR+ (www.sedarplus.ca). The final voting results of all matters voted on at the meeting will also be filed on SEDAR+.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people heal and get well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic drug therapy. The Numinus model, which includes psychedelic drug research, clinic care and practitioner training, is at the forefront of change to heal, rather than manage, the symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, we are integrating psychedelic drug therapy into mainstream clinical practice, building the foundation for a healthier society.
For more information, visit www.numinus.com, LinkedIn, Facebook, twitterand Instagram.
Forward-Looking Statements
The stock exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of this information. The contents of this press release are forward-looking statements. Statements and other information contained in this press release concerning anticipated future events are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seeks,” “anticipates,” “believes,” “plans,” “estimates,” “expects” and “intends” and statements that events “may,” “will,” “should,” “might” or “might occur” or other similar expressions. Forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those contained in the forward-looking statements, including the risks described in our Annual Information Form dated November 25, 2015. November 29, 2023 Numinus also makes available forward-looking statements on SEDAR+ at www.sedarplus.ca. Forward-looking statements are based on management’s expectations and opinions as of the date the statements are made. Numinus undertakes no obligation to update forward-looking statements if circumstances or management’s expectations or opinions should change, except as required by applicable law. Investors should not place undue reliance on forward-looking statements.
SOURCE Numinus Wellness Inc.
